Skip to main content
OpenTrials
Completed

NCT Number: NCT05757427

Pilot Clinical Evaluation of a Microwave Imaging System for Breast Cancer Detection

The trialed investigational medical imaging device is a low-power microwave breast imaging system for cancer screening purposes. It is an active device which uses non-ionizing radiation.

Microwave imaging is an emerging imaging modality for the early detection of breast cancer. The physical basis of microwave imaging is the dielectric contrast between healthy and cancerous breast tissues at the microwave frequency spectrum.

This study is a pilot Clinical Evaluation of a microwave imaging system (Wavelia #2) for Breast Cancer Detection. The clinical data that will be collected in the context of this study is intended for the assessment of the imaging diagnostic capability and the safety of the investigational device.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Galway University Hospital/Symptomatic Breast Unit

Galway, Ireland

About this study

This study aims to enrol approximately 103 subjects presenting to the symptomatic breast unit with a breast abnormality who consent to undergo an Microwave Breast Imaging (MWBI) scan using the Wavelia #2 imaging system. The study uses an adaptive design to verify and validate the technical evolutions that have been integrated in the Wavelia# 2 prototype on a small patient dataset (30 patients). Once the technical performance has been established recruitment will continue to assess the clinical performance of the MBI system compared to standard of care reference imaging. The primary objectives of the study are to assess the performance of Wavelia # 2 in the detection of malignant and benign breast lesions, the sizing of malignant lesions for which post-surgery histology data will be available and the differentiation between benign and malignant breast abnormalities by means of features extracted from the MBI images.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed Consent
  • Female subjects with an investigator assessed discrete breast abnormality of size > 1cm
  • Able and willing to comply with the requirements of this study protocol
  • Negative urine pregnancy test on the day of microwave imaging procedure (if of childbearing potential)
  • intact breast skin (i.e., without bleeding lesion, no evidence of inflammation and/or erythema of the breast)
  • Able to comfortably lie reasonably still in a prone position for approximately 15 minutes
  • Have had biopsy more than 2 weeks prior to the microwave breast investigation (if applicable)

Exclusion criteria

  • Have a cup size of A or whose breast is deemed too small to allow MBI assessment in the opinion of the investigator
  • Are pregnant or breast-feeding
  • Have had surgery on either breast within the past 12 months
  • Have any active or metallic implant other than a biopsy clip
  • Would be unsuitable for an MBI scan or unlikely to follow the protocol in the opinion of the Investigator

Treatment and study plan

Wavelia #2

Device

Patients who are eligible and consent to have an MBI breast scan procedure will be asked to confirm their willingness to participate on the day of the breast scan. The patient will first have an Optical Breast Contour Detection (OBCD) scan, to reconstruct the external surface of the breast with high-precision, measure the total volume and the vertical extent of the breast before the MBI scan. The MBI scan will be performed on both breasts. The process will include optimization of breast positioning and breast cleaning to remove any transition liquid remaining on the skin.

Primary outcomes

  1. Assess the Detectability Rate of Malignant and Benign Breast Lesions.

    Time frame: 21 days

    Endpoint: Percentage of malignant and benign breast lesions correctly detected with Wavelia MWBI

Secondary outcomes

  1. Correct Sizing of Breast Lesions With Wavelia MWBI

    Time frame: 21 days

    Endpoint: Maximal linear size difference (in mm) between the MWBI lesion detection and the maximal size reported in the ultrasound lesion size estimates. This is measured as a continuous variable of difference in mm

Other outcomes

  1. Evaluate the Wavelia MWBI Breast Lesion Detectability Rate on Patients With no Biopsy Clip

    Time frame: 21 days

    Endpoint: Percentage of breast lesions correctly detected with Wavelia MWBI on patients with no biopsy clip marking in their breast

  2. Safety Objective: Provide Further Data to Support the Establishment of the Safety Profile of MWBI Scan

    Time frame: 21 days

    Endpoint: Incidence of Serious Adverse Events and Serious Adverse Device Effects during the total duration of the trial as well as other adverse events reported.

Sponsors and collaborators

Lead sponsor

MVG Industries SAS

Industry

Registry information

Official study title

Open-label,Single Site,Pilot Clinical Investigation to Assess Detectability and Sizing of Invasive Breast Cancers,Detectability of Benign Breast Lesions,Differentiation Between Malignant and Benign Breast Lesions Using Wavelia # 2

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Mar 7, 2023
Registry last updated
Nov 26, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.